HR+ HER2- Metastatic Breast Cancer Medical Management

HR+ HER2- Metastatic Breast Cancer Medical Management

Multi-centre programs can request up to $250,000 & uni-lateral request can apply up to $50,000. - Due date is Sep 22, 2021

Pfizer
Healthcare professionals need to understand the latest scientific data in order to make evidence-based treatment decisions and provide optimal care for patients with ER+ HER2- metastatic breast cancer.

Funding Opportunity

Visit the funding page (members only, sign in): HR+ HER2- Metastatic Breast Cancer Medical Management

Sign in or register for free to read the full details and apply

Sign in Create a free account

Share:

All funding opportunities